Chugai Pharmaceutical Co., Ltd. (TYO:4519)
Japan
· Delayed Price · Currency is JPY 8,233.00
-239.00 (-2.82%)
At close: Dec 5, 2025
Chugai Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 1,042,161 | 997,901 | 974,493 | 1,039,247 | 802,836 | 633,314 | Upgrade
|
| Other Revenue | 171,552 | 172,710 | 136,874 | 220,699 | 196,923 | 153,632 | Upgrade
|
| Revenue | 1,213,713 | 1,170,611 | 1,111,367 | 1,259,946 | 999,759 | 786,946 | Upgrade
|
| Revenue Growth (YoY) | 6.25% | 5.33% | -11.79% | 26.02% | 27.04% | 14.68% | Upgrade
|
| Cost of Revenue | 370,432 | 339,409 | 413,306 | 476,251 | 338,147 | 273,465 | Upgrade
|
| Gross Profit | 843,281 | 831,202 | 698,061 | 783,695 | 661,612 | 513,481 | Upgrade
|
| Selling, General & Admin | 111,954 | 110,098 | 112,580 | 100,760 | 102,416 | 94,401 | Upgrade
|
| Research & Development | 187,420 | 181,440 | 174,868 | 149,626 | 137,299 | 117,850 | Upgrade
|
| Other Operating Expenses | -9,321 | -2,339 | -28,561 | - | - | - | Upgrade
|
| Operating Expenses | 290,053 | 289,199 | 258,887 | 250,386 | 239,715 | 212,251 | Upgrade
|
| Operating Income | 553,228 | 542,003 | 439,174 | 533,309 | 421,897 | 301,230 | Upgrade
|
| Interest Expense | -112 | 5 | -27 | -61 | -48 | -62 | Upgrade
|
| Interest & Investment Income | - | 1,027 | 4,674 | 52 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 292 | -1 | - | -2,134 | -2,464 | -2,980 | Upgrade
|
| EBT Excluding Unusual Items | 553,408 | 543,034 | 443,821 | 531,166 | 419,385 | 298,188 | Upgrade
|
| Pretax Income | 553,408 | 543,034 | 443,821 | 531,166 | 419,385 | 298,188 | Upgrade
|
| Income Tax Expense | 156,247 | 155,717 | 118,349 | 156,737 | 116,390 | 83,455 | Upgrade
|
| Earnings From Continuing Operations | 397,161 | 387,317 | 325,472 | 374,429 | 302,995 | 214,733 | Upgrade
|
| Net Income | 397,161 | 387,317 | 325,472 | 374,429 | 302,995 | 214,733 | Upgrade
|
| Net Income to Common | 397,161 | 387,317 | 325,472 | 374,429 | 302,995 | 214,733 | Upgrade
|
| Net Income Growth | 2.63% | 19.00% | -13.08% | 23.58% | 41.10% | 36.29% | Upgrade
|
| Shares Outstanding (Basic) | 1,646 | 1,645 | 1,645 | 1,645 | 1,644 | 1,643 | Upgrade
|
| Shares Outstanding (Diluted) | 1,646 | 1,646 | 1,645 | 1,645 | 1,645 | 1,645 | Upgrade
|
| Shares Change (YoY) | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | 0.03% | Upgrade
|
| EPS (Basic) | 241.35 | 235.39 | 197.83 | 227.64 | 184.29 | 130.66 | Upgrade
|
| EPS (Diluted) | 241.34 | 235.36 | 197.80 | 227.57 | 184.17 | 130.53 | Upgrade
|
| EPS Growth | 2.63% | 18.99% | -13.08% | 23.57% | 41.09% | 36.24% | Upgrade
|
| Free Cash Flow | 350,349 | 397,185 | 337,977 | 181,487 | 213,657 | 147,995 | Upgrade
|
| Free Cash Flow Per Share | 212.89 | 241.36 | 205.40 | 110.30 | 129.87 | 89.96 | Upgrade
|
| Dividend Per Share | 107.000 | 98.000 | 80.000 | 78.000 | 76.000 | 55.000 | Upgrade
|
| Dividend Growth | 32.10% | 22.50% | 2.56% | 2.63% | 38.18% | 71.88% | Upgrade
|
| Gross Margin | 69.48% | 71.01% | 62.81% | 62.20% | 66.18% | 65.25% | Upgrade
|
| Operating Margin | 45.58% | 46.30% | 39.52% | 42.33% | 42.20% | 38.28% | Upgrade
|
| Profit Margin | 32.72% | 33.09% | 29.29% | 29.72% | 30.31% | 27.29% | Upgrade
|
| Free Cash Flow Margin | 28.87% | 33.93% | 30.41% | 14.40% | 21.37% | 18.81% | Upgrade
|
| EBITDA | 579,513 | 573,668 | 470,914 | 564,743 | 452,765 | 331,606 | Upgrade
|
| EBITDA Margin | 47.75% | 49.01% | 42.37% | 44.82% | 45.29% | 42.14% | Upgrade
|
| D&A For EBITDA | 26,285 | 31,665 | 31,740 | 31,434 | 30,868 | 30,376 | Upgrade
|
| EBIT | 553,228 | 542,003 | 439,174 | 533,309 | 421,897 | 301,230 | Upgrade
|
| EBIT Margin | 45.58% | 46.30% | 39.52% | 42.33% | 42.20% | 38.28% | Upgrade
|
| Effective Tax Rate | 28.23% | 28.68% | 26.67% | 29.51% | 27.75% | 27.99% | Upgrade
|
| Revenue as Reported | 1,213,713 | - | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.